Callos Andrew

EVP, Chief Commercial OfficerCYTOKINETICS INC (CYTK) · full profile →Form 4 · filed Apr 30, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$949K
Net Open-Market Flow
-$949K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 30, 2026Option exercise(M)15K$23.26$349K74K
Apr 30, 2026Sell(S)15K$63.26$949K59K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 30, 2026Option exercise(M)15K$054K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001061983-26-000045) within minutes of acceptance. Every field above traces to the original document. Verify it directly: